4.3 Article

Metabolic characteristics of [18F]fluoroboronotyrosine (FBY) PET in malignant brain tumors

Journal

NUCLEAR MEDICINE AND BIOLOGY
Volume 106, Issue -, Pages 80-87

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.nucmedbio.2022.01.002

Keywords

-

Funding

  1. Ministry of Science and Technology of the People's Republic of China [2021YFA1601400, 2017YFA0506300]
  2. Beijing Municipal Natural Science Foundation [7202150, Z200018, 19JCZDJC64200]
  3. Special Foundation of Beijing Municipal Education Commission [3500-12020123]
  4. National Nature Science Foundation of China [U1867209, 21778003]
  5. Li Ge-Zhao Ning Life Science Youth Research Foundation [LGZNQN202004]
  6. Tsinghua University-Peking Union Medical College Hospital Initiative Scientific Research Program [2019ZLH101]

Ask authors/readers for more resources

This study investigated the imaging characteristics of [F-18]fluoroboronotyrosine (FBY) positron emission tomography (PET) in malignant brain tumors. The results showed that elevated FBY uptake can be seen in most malignant brain tumors, and primary glioblastoma (GBM), recurrent glioma, and metastatic brain tumor displayed a significant tumor-to-background ratio.
Objective: [F-18]fluoroboronotyrosine (FBY) is a large neutral amino acid transporter 1 (LAT-1) dependent boron-derived tyrosine which has diagnostic and therapeutic potentiality. This study aimed to investigate the imaging characteristics of FBY positron emission tomography (PET) in malignant brain tumors. Methods: A total of 35 patients with 36 lesions were prospectively enrolled for FBY positron emission tomography (PET) and magnetic resonance imaging (MRI). Three-dimensional region of interest was semiautomatically defined on MRI and coregistered to FBY PET images. Five quantitative parameters, namely, standardized uptake value (SUV) maximum (SUVmax), SUVmean, metabolic tumor volume (MTV), total lesion activity (TLA) and tumor-to-normal ratio (T/N ratio), were calculated. The mean and standard deviation values of the parameters in different circumstances were calculated, and the Wilcoxon rank-sum test was applied to reveal the differences of FBY parameters. Results: The maximum and mean standardized uptake value (SUV) of the normal brain were 0.119 +/- 0.030 and 0.038 +/- 0.017 in the study cohort. Majority of the neoplastic lesions displayed elevated FBY uptake, with SUVmax of 0.26 +/- 0.14, 3.00 +/- 0.61, 2.30 +/- 0.51, 2.62 +/- 0.36, and T/N ratio of 2.2 +/- 1.3, 22.6 +/- 6.6, 23.7 +/- 8.3, 20.2 +/- 3.8 for primary lower grade glioma (LGG), primary glioblastoma (GBM), recurrent diffuse glioma and metastatic brain tumor, respectively. Primary GBM showed significantly higher SUVmax, SUVmean and T/N ratio than primary LGG (p = 0.015-0.032). Meanwhile, 1 gliosis and 1 stable disease were also included and exhibited minimum FBY activity, with SUVmax of 0.17 and 0.33, T/N ratio of 1.04 and 2.58, respectively. Conclusion: Elevated FBY activity can be seen in most malignant brain tumors, and primary GBM, recurrent glioma and metastatic brain tumor displayed significant tumor to background ratio, which may facilitate the malignancy stratification and future boron neutron capture therapy. (c) 2022 Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Radiology, Nuclear Medicine & Medical Imaging

18F-Boramino acid PET/CT in healthy volunteers and glioma patients

Zhu Li, Ziren Kong, Junyi Chen, Jiyuan Li, Nan Li, Zhi Yang, Yu Wang, Zhibo Liu

Summary: The study found that F-18-FBY is well tolerated by healthy volunteers with rapid clearance and excretion profile. In glioma patients, F-18-FBY uptake increased with tumor grade and showed positive correlations with LAT-1 expression and Ki-67 labeling index. The PET tracer has potential in assessing LAT-1 expression and guiding boron neutron capture therapy in gliomas.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

Article Chemistry, Multidisciplinary

Desilylation Induced by Metal Fluoride Nanocrystals Enables Cleavage Chemistry In Vivo

Dongban Duan, Hao Dong, Zhiyu Tu, Chunhong Wang, Qunfeng Fu, Junyi Chen, Haipeng Zhong, Ping Du, Ling-Dong Sun, Zhibo Liu

Summary: Metal fluoride nanocrystals can induce controlled release of fluorophores and drug molecules in various biological systems through desilylation cleavage chemistry. The use of biocompatible PEG-coated CaF2 nanocrystals has shown efficient release of functional molecules. This strategy has also been applied to prodrug activation with remarkable anticancer effects and minimal side effects, empowering metal fluoride nanocrystals for further biological applications.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2021)

Article Chemistry, Multidisciplinary

Isolation of 212Pb from natural thorium for targeted alpha-therapy

Junyi Chen, Mengxin Xu, Yu Liu, Dongban Duan, Yuxiang Han, Zhibo Liu

Summary: Targeted alpha-therapy (TAT) is a promising treatment for cancer with excellent efficacy. However, the supply of alpha-emitters for TAT is limited, and Pb-212 extracted from natural thorium has the potential to meet this demand. Researchers have developed a practical method to isolate Pb-212 from natural thorium, which could be an important breakthrough in the field.

CHINESE CHEMICAL LETTERS (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy

Pu Zhang, Mengxin Xu, Jie Ding, Junyi Chen, Taiping Zhang, Li Huo, Zhibo Liu

Summary: The study successfully conjugated two fatty acids (lauric acid and palmitic acid) to FAPI-04 to form two albumin-binding FAPI radiopharmaceuticals, FAPI-C12 and FAPI-C16. They exhibited high binding affinity to FAP, stable in circulation, and significantly increased tumor uptake and retention, showing potential for CAF-targeted radionuclide therapy.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy

Mengxin Xu, Pu Zhang, Jie Ding, Junyi Chen, Li Huo, Zhibo Liu

Summary: This study developed and evaluated two albumin-binder conjugated FAPI radiopharmaceuticals (TEFAPI-06 and TEFAPI-07) to address the issue of fast clearance and insufficient tumor retention. The results showed significantly improved tumor accumulation and retention compared to the original FAPI tracer, and these radiopharmaceuticals demonstrated remarkable growth inhibition of PDX tumors with negligible side effects.

JOURNAL OF NUCLEAR MEDICINE (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Larger 18F-fluoroboronotyrosine (FBY) active volume beyond MRI contrast enhancement in diffuse gliomas than in circumscribed brain tumors

Ziren Kong, Zhu Li, Junyi Chen, Wenbin Ma, Yu Wang, Zhi Yang, Zhibo Liu

Summary: This study investigated the relationship between FBY PET- and MRI-defined tumor volumes in contrast-enhanced diffuse gliomas and circumscribed brain tumors. The results showed that the MRI-defined tumor volume was smaller than the FBY-defined tumor volume and mostly contained within it. There was a significant difference in the DICE score between circumscribed tumors and diffuse tumors, but for regions with increased FBY metabolism and no MRI contrast enhancement, both types of tumors showed similar SUVmean values.

EJNMMI RESEARCH (2022)

Article Medicine, Research & Experimental

86Y-Labeled Albumin-Binding Fibroblast Activation Protein Inhibitor for Late-Time-Point Cancer Diagnosis

Jie Ding, Mengxin Xu, Junyi Chen, Pu Zhang, Li Huo, Ziren Kong, Zhibo Liu

Summary: This study synthesized and evaluated four albumin-binding fibroblast activation protein inhibitors (FAPIs), finding that TE-FAPI-04 demonstrated the most favorable pharmacokinetics and imaging performance.

MOLECULAR PHARMACEUTICS (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Organotrifluoroborate enhances tumor targeting of fibroblast activation protein inhibitors for targeted radionuclide therapy

Yu Liu, Haocheng Tang, Tianchi Song, Mengxin Xu, Junyi Chen, Xi-Yang Cui, Yuxiang Han, Zhu Li, Zhibo Liu

Summary: In this study, the use of alpha-emitter Bi-213 and FAP inhibitors with an organotrifluoroborate linker led to improved tumor uptake, reduced side effects, and significant suppression of tumor growth.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

Novel boron-containing amino acid analogs for tumor positron tomography and boron neutron capture therapy

Junyi Chen, Zhibo Liu, Mengxin Xu

NUCLEAR MEDICINE AND BIOLOGY (2022)

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

Development of FAP targeted radiopharmaceuticals

Mengxin Xu, Zhibo Liu, Junyi Chen, Pu Zhang

NUCLEAR MEDICINE AND BIOLOGY (2022)

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

The Cyclotron Production of Actinium-225 in CYCIAE-100

Junyi Chen, Zhibo Liu

JOURNAL OF NUCLEAR MEDICINE (2021)

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

Albumin Binders for Tumor Enhanced FAPI Radioligand Retention

Mengxin Xu, Jie Ding, Pu Zhang, Junyi Chen, Zhibo Liu

JOURNAL OF NUCLEAR MEDICINE (2021)

Meeting Abstract Oncology

PET-CT/FACS platform to detect the biodistribution of radioisotope 89Zr PD-1 inhibitor in syngeneic tumor models

Xuzhen Tang, Fuyang Wang, Junyi Chen, Xuanming Zeng, Zhibo Liu, Qunsheng Ji

CANCER RESEARCH (2020)

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

177Lu-labeled αPD-L1 antibody synergizes with an immune checkpoint inhibitor for colorectal tumors

Jingyun Ren, Mengxin Xu, Junyi Chen, Jiyuan Li, Peipei Wang, Jie Ding, Li Huo, Fang Li, Zhibo Liu

JOURNAL OF NUCLEAR MEDICINE (2020)

No Data Available